Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant 20 mg in abdominal obesity with microalbuminuria
2006-002951-33Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Abdominal adiposity (ABCD), type 2 diabetes mellitus (T2DM), lipid disorder and 1 more comparing Rimonabant 20 mg with Placebo (2 arms). Primary endpoint: Change in microalbuminuria at 12 months. Started Jan 2015; status: completed.
02
Drugs
rimonabant
03
Conditions
Abdominal adiposity (ABCD)type 2 diabetes mellitus (T2DM)lipid disorderMicroalbuminuria
Beyond the preview
Go deeper on 2006-002951-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002951-33.